Established in 2012, Junshi Biosciences is an innovation-driven biopharmaceutical company committed to developing first-in-class and best-in-class drugs through original innovation.
With an outstanding capacity for innovative drug discovery, advanced biotechnology research and development, a whole-industry-chain approach with large-scale production technology, and drug combinations with great market potential, Junshi Biosciences has endless potential in onco-immunotherapy as well as the treatment of autoimmune diseases, metabolic diseases, neurological diseases and infectious diseases.
With strong R&D capacity, Junshi Biosciences is at the cutting-edge of medical innovation. Our mission is to"Provide patients with world-class, trustworthy, affordable, and innovative drugs".
To provide patients with treatment options that work better and cost less
To develop first-in-class and best-in-class drugs through original innovation
To become a pioneer in the area of translational medicine
To fulfill unmet medical needs and provide the best treatments for patients
Rapidly expand our
product pipeline
Focus on the advancement and commercialization of
existing drug candidates
Scale up our macromolecule fermentation capacity and
lower production cost
We aim to become an innovative and globally competitive biopharmaceutical company with a whole-industry-chain layout that encompasses R&D, manufacturing and commercialization.
Year
In China, For Global
Starting from its global headquarters in Shanghai, Junshi Biosciences has established four R&D centers in Shanghai, Suzhou, San Francisco and Maryland, and two monoclonal antibody production bases in Wujiang, Suzhou and Lingang, Shanghai.
Headquarters
Shanghai Innovation Center
Shanghai Lingang Production Base
Suzhou Innovation Center
Suzhou Wujiang Production Base
Maryland Innovation Center
San Francisco Innovation Center